Global search

Find data and evidence

Type at least 2 characters. Use arrow keys to review and Enter to open.

Peer reviewedOpen accessTuberculosis

Population-level health and economic impacts of introducing Vaccae vaccination in China: a modelling study

BMJ Global Health·

Jun-Jie Mao, Xiao Zang, Wan-Lu Yue, Pei-Yao Zhai, Qiong Zhang, Chun-Hu Li, Xun Zhuang, Min Liu, Gang Qin

DOI
10.1136/bmjgh-2023-012306
PMID
37257938
PMCID
PMC10254880
OpenAlex
Study type
Mathematical modelling
Publisher
BMJ
Article type
journal-article
Integrity
current

Why this research matters now

The study addresses TB control in the context of population ageing in China and may support evidence-based decisions on TB vaccination strategy and reimbursement.

01

Structured evidence summary

Research question

The study evaluates the population-level health and economic impacts of introducing the Vaccae TB vaccine in China to inform vaccination policy.

Study design

A modelling study using an age-structured compartmental model, with cost analyses from the healthcare sector perspective discounted at 3%, comparing three vaccination scenarios.

Population and setting

The setting is a national TB vaccination programme in China initiated in 2024, evaluating three strategies: no Vaccae, mass vaccination of people aged 15-74 years, and targeted vaccination of older adults aged 60 years.

Main findings

Targeted vaccination of older adults modestly reduced TB burden (~20%), averting an estimated 8.01 million TB cases and 0.20 million deaths over 2024-2050, with an ICER of US$4,387 per DALY averted and a total budget of about US$22.5 billion. Mass vaccination produced a larger impact on TB incidence but with substantially higher costs. Both preinfection and postinfection efficacy types could yield incidence reductions exceeding 40% in 2050, provided the vaccine price remains ≤US$5 per dose.

Public-health relevance

The study addresses TB control in the context of population ageing in China and may support evidence-based decisions on TB vaccination strategy and reimbursement.

Important limitations

Limitations are not explicitly stated in the supplied abstract. This summary is limited to the supplied single-article abstract/metadata and requires the original paper for decision-grade interpretation.

GIDS interpretation

The article is indexed under tuberculosis, vaccination, health policy, and transmission dynamics, and is discoverable as a modelling-based evaluation of a specific TB vaccine candidate in China. No connection to a live surveillance signal is made.

02

Related GIDS surveillance

Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.

03

Evidence relationships

This article has 10 auditable classifier relationships to diseases, places, topics, and study design.

about diseaseaddresses topicaddresses topicaddresses topicaddresses topicevaluates interventioninforms policy domainstudied instudied population settinguses study design